• 1
    2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21: 10111053.
  • 2
    The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003; 289: 25602572.
  • 3
    Birkenhager WH, de Leeuw PW. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens. 1999; 17: 873881.
  • 4
    Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000; 355: 637645.
  • 5
    Linz W, Wiemer G, Gohlke P, et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995; 47: 2549.
  • 6
    Benter IF, Ferrario CM, Morris M, et al. Antihypertensive actions of angiotensin-(1–7) in spontaneously hypertensive rats. Am J Physiol. 1995; 269: H313H319.
  • 7
    Ichiki T, Labosky PA, Shiota C, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 1995; 377: 748750.
  • 8
    Barber MN, Sampey DB, Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension. 1999; 34: 11121116.
  • 9
    Sever PS, Chang CL. Discordant responses to two classes of drugs acting on the renin-angiotensin system. J Renin Angiotensin Aldosterone Syst. 2001; 2: 2530.
  • 10
    Stergiou GS, Skeva II, Baibas NM, et al. Does the antihypertensive response to angiotensin converting enzyme inhibition predict the antihypertensive response of angiotensin receptor antagonism? Am J Hypertens. 2001; 14: 688693.
  • 11
    O'Brien E, Petrie J, Littler W, et al. The British Hypertension Society protocol for the evaluation of blood pressure measuring devices. J Hypertens. 1993;11(suppl 2):S43S62.
  • 12
    Altman DG. Analysis of crossover trials. In: Practical Statistics for Medical Research. Chapman & Hall, eds. London , England : CRC Press; 1991:467471.
  • 13
    Gill JS, Zezulka AV, Beevers DG, et al. Relation between initial blood pressure and its fall with treatment. Lancet. 1985; 1: 567569.
  • 14
    Stergiou GS, Efstathiou SP, Roussias LG, et al. Blood pressure and pulse pressure lowering effects, trough: peak ratio and smoothness index of telmisartan compared to lisinopril. J Cardiovasc Pharmacol. 2003; 42: 491496.
  • 15
    Stergiou GS, Baibas NM, Gantzarou AP, et al. Reproducibility of home, ambulatory and clinic blood pressure: Implications for the design of trials for the assessment of antihypertensive drug efficacy. Am J Hypertens. 2002; 15: 101104.
  • 16
    O'Brien E, Asmar R, Beilin L, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003; 21: 821848.
  • 17
    Lacourciere Y, Lenis J, Orchard R, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blocker telmisartan and amlodipine. Blood Press Monit. 1998; 3: 295302.
  • 18
    Elliot HL. The efficacy and safety of telmisartan compared to atenolol and placebo in patients with hypertension [abstract]. Am J Hypertens. 1998;11:124A.
  • 19
    Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens. 1999; 17: 293302.
  • 20
    Mallion J, Siche J, Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens. 1999; 13: 657664.
  • 21
    Littlejohn T, Mroczek W, Marbury T, et al. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol. 2000; 16: 11231132.
  • 22
    Neutel JM, Kolloch RE, Plouin PF, et al. Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mildto- moderate essential hypertension-a randomised ABPM study. J Hum Hypertens. 2003; 17: 569575.
  • 23
    Messerli FH, Kaesser UR. Lisinopril in the treatment of hypertension. J Hum Hypertens. 1989;3(suppl 1):1721.
  • 24
    Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet. 1999; 353: 20082013.
  • 25
    Chalmers J, Wing L, Taylor S. Analysis of time trends, individual subject responses and background variation in crossover factorial studies with antihypertensive drugs. J Hypertens. 1990;8(suppl 4):S27S35.
  • 26
    Attwood S, Bird R, Burch K, et al. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens. 1994; 12: 10531060.
  • 27
    Bidiville J, Nussberger J, Waeber G, et al. Individual responses to converting enzyme inhibitors and calcium antagonists. Hypertension. 1988; 11: 166173.
  • 28
    Niutta E, Cusi D, Colombo R, et al. Predicting interindividual variations in antihypertensive therapy: the role of sodium transport systems and renin. J Hypertens. 1990;8(suppl 4):S53S58.
  • 29
    Stergiou GS, Skeva II, Baibas NM, et al. Additive hypotensive effect of angiotensin converting enzyme inhibition and angiotensin receptor antagonism in essential hypertension. J Cardiovasc Pharmacol. 2000; 35: 937941.
  • 30
    Azizi M, Linhart A, Alexander J, et al. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens. 2000; 18: 11391147.
  • 31
    Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000; 321: 14401444.